Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the role of glucagon action in the metabolic phenotype of untreated insulin deficiency. RESEARCH DESIGN AND METHODS: We compared pertinent clinical and metabolic parameters in glucagon receptor-null (Gcgr−/−) mice and wild-type (Gcgr+/+) controls after equivalent destruction of β-cells. We used a double dose of streptozotocin to maximize β-cell destruction. RESULTS: Gcgr+/+ mice became hyperglycemic (>500 mg/dL), hyperketonemic, polyuric, and cachectic and had to be killed after 6 weeks. Despite comparable β-cell destruction in Gcgr−/− mice, none of the foregoing clinical or laboratory manifestations of diabetes appeared. There was marked α-cell hyperplasia and hyperglucagonemia (∼1,200 pg/mL), but hepatic phosphorylated cAMP response element binding protein and phosphoenolpyruvate carboxykinase mRNA were profoundly reduced compared with Gcgr+/+ mice with diabetes—evidence that glucagon action had been effectively blocked. Fasting glucose levels and oral and intraperitoneal glucose tolerance tests were normal. Both fasting and nonfasting free fatty acid levels and nonfasting β-hydroxy butyrate levels were lower. CONCLUSIONS: We conclude that blocking glucagon action prevents the deadly metabolic and clinical derangements of type 1 diabetic mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While lack of GCGR signaling can normalize glycemia under insulin-deficient conditions15,16, this effect is contingent on the presence of residual insulin17.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundSelf-citationGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563 · cited 5×
“Male mice with global glucagon receptor knockout and wild-type mice (19)”
BackgroundSelf-citationGerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundTHE EFFECTS OF TOTAL STARVATION UPON THE LEVELS OF CIRCULATING GLUCAGON AND INSULIN IN MAN*
Unger, R. H., Eisentraut, A. M., & Madison, L. L. (1963) · Journal of Clinical Investigation · doi:10.1172/jci104788 · Cited by 345 · cited 1×
“Glucagon was immunocytochemically localized to pancreatic a-cells (3) and shown to be secreted in response to increased glucose need, as in starvation and exercise (4).”
BackgroundSelf-citationLeptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327 · cited 6×
“The search for more practical suppressors or antagonists of glucagon has been reenergized by the recent demonstration that leptin can suppress diabetic hyperglucagonemia and reverse the catabolic effects of complete insulin deficiency for extended periods without apparent negative consequences (11,12).”
BackgroundResultSelf-citationCREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ
Herzig, S., Hedrick, S., Morantte, I., Koo, S.-H., Galimi, F., & Montminy, M. (2003) · Nature · doi:10.1038/nature02110 · Cited by 321 · cited 2×
“Uncontrolled insulin deficiency with hyperglucagonemia is characterized by increased gluconeogenesis associated with upregulation of the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEPCK) (29,30).”
BackgroundInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast to normal a-cells, which are restrained by the high local concentrations of intraislet insulin (22), type 1 diabetic a-cells are unregulated, which results in inappropriate hyperglucagonemia (5).”
BackgroundSelf-citationAntidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Hedbacker, K., Birsoy, K., Wysocki, R. W., Asilmaz, E., Ahima, R. S., Farooqi, I. S., & Friedman, J. M. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.007 · Cited by 280 · cited 2×
“More recently, the same antidiabetic efficacy has been demonstrated with recombinant leptin (11,23).”
BackgroundUnger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1962) · Journal of Clinical Investigation · doi:10.1172/jci104525 · Cited by 278 · cited 1×
“The development of a radioimmunoassay for glucagon (1) established the hormonal status of this peptide (2), originally considered to be a contaminant of the insulin extraction process.”
BackgroundSelf-citationRole of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis
Meyer, C., Dostou, J. M., Welle, S. L., & Gerich, J. E. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00032.2001 · Cited by 269 · cited 1×
“(35) indicate that in normal humans 90% of ingested glucose is taken up by liver, muscle, brain, and kidney, and hepatic glucose release declines 82%.”
BackgroundHypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes.
Orci, L., Baetens, D., Rufener, C., Amherdt, M., Ravazzola, M., Studer, P., Malaisse-Lagae, F., & Unger, R. H. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.4.1338 · Cited by 255
Self-citationGlucagon: Role in the Hyperglycemia of Diabetes Mellitus
Dobbs, R., Sakurai, H., Sasaki, H., Faloona, G., Valverde, I., Baetens, D., Orci, L., & Unger, R. (1975) · Science · doi:10.1126/science.1089999 · Cited by 229 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundSelf-citationConarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224 · cited 5×
“Because Gcgr mice are resistant to STZ-induced b-cell destruction (24), it was necessary to use a double dose of the b-cell poison STZ.”
BackgroundResultSelf-citationHyperglucagonemia in diabetic ketoacidosis
Müller, W. A., Faloona, G. R., & Unger, R. H. (1973) · The American Journal of Medicine · doi:10.1016/0002-9343(73)90083-1 · Cited by 220 · cited 2×
“By 1973, it was recognized that a-cell function was grossly abnormal in diabetes, particularly in type 1 diabetes (5).”
BackgroundSelf-citationSloop, K. W., Cao, J. X.-C., Siesky, A. M., Zhang, H. Y., Bodenmiller, D. M., Cox, A. L., Jacobs, S. J., Moyers, J. S., Owens, R. A., Showalter, A. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420911 · Cited by 219 · cited 1×
“Diabetic mice with glucagon receptor knockout (19) or mice treated with Gcgr antisense oligonucleotide similarly benefit from the elimination of glucagon action (20,21).”
BackgroundMaking insulin-deficient type 1 diabetic rodents thrive without insulin
Yu, X., Park, B.-H., Wang, M.-Y., Wang, Z. V., & Unger, R. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806993105 · Cited by 219 · cited 13×
“The search for more practical suppressors or antagonists of glucagon has been reenergized by the recent demonstration that leptin can suppress diabetic hyperglucagonemia and reverse the catabolic effects of complete insulin deficiency for extended periods without apparent negative consequences (11,12).”
BackgroundSelf-citationPetersen, K. F., & Sullivan, J. T. (2001) · Diabetologia · doi:10.1007/s001250100006 · Cited by 209
Liang, Y., Osborne, M. C., Monia, B. P., Bhanot, S., Gaarde, W. A., Reed, C., She, P., Jetton, T. L., & Demarest, K. T. (2004) · Diabetes · doi:10.2337/diabetes.53.2.410 · Cited by 202 · cited 1×
“Diabetic mice with glucagon receptor knockout (19) or mice treated with Gcgr antisense oligonucleotide similarly benefit from the elimination of glucagon action (20,21).”
BackgroundHyperglucagonemia and Its Suppression: Importance in the Metabolic Control of Diabetes
Raskin, P., & Unger, R. H. (1978) · New England Journal of Medicine · doi:10.1056/nejm197808312990901 · Cited by 196 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundSelf-citationGlucagon Antibodies and Their Use for Immunoassay for Glucagon.
Unger, R. H., Eisentraut, A. M., McCall, M. S., Keller, S., Lanz, H. C., & Madison, L. L. (1959) · Experimental Biology and Medicine · doi:10.3181/00379727-102-25338 · Cited by 177 · cited 1×
“The development of a radioimmunoassay for glucagon (1) established the hormonal status of this peptide (2), originally considered to be a contaminant of the insulin extraction process.”
BackgroundSelf-citationHyperglycemia of Diabetic Rats Decreased by a Glucagon Receptor Antagonist
Johnson, D. G., Goebel, C. U., Hruby, V. J., Bregman, M. D., & Trivedi, D. (1982) · Science · doi:10.1126/science.6278587 · Cited by 166
Wang, M.-Y., Orci, L., Ravazzola, M., & Unger, R. H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509001102 · Cited by 151 · cited 1×
“were performed in triplicate as previously described (25).”
MethodSelf-citationAmino Acid Deficiency and the Skin Rash Associated with Glucagonoma
Norton, J. A., KAHN, C. R., SCHIEBINGER, R., GORSCHBOTH, C., & BRENNAN, M. F. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-2-213 · Cited by 137 · cited 1×
“Amino acid deficiency has been described in glucagonoma patients (33,34), raising the possibility that Gcgr mice might have high amino acid levels, as reported by Boden et al.”
BackgroundAyala, J. E., Bracy, D. P., James, F. D., Julien, B. M., Wasserman, D. H., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-0945 · Cited by 125 · cited 1×
“Alternatively, the elevated glucagon-like peptide 1 levels might have increased muscle glucose uptake (32).”
BackgroundEffects of glucagon on plasma amino acids.
Boden, G., Rezvani, I., & Owen, O. E. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111272 · Cited by 123 · cited 2×
“(31) in humans in whom glucagon was suppressed by somatostatin.”
BackgroundPersistent Pancreatic Glucagon but not Insulin Response to Arginine in Pancreatectomized Dogs
MASHITER, K., HARDING, P. E., CHOU, M., MASHITER, G. D., STOUT, J., DIAMOND, D., & FIELD, J. B. (1975) · Endocrinology · doi:10.1210/endo-96-3-678 · Cited by 109
A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects
Qureshi, S. A., Rios Candelore, M., Xie, D., Yang, X., Tota, L. M., Ding, V. D.-H., Li, Z., Bansal, A., Miller, C., Cohen, S. M., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3267 · Cited by 109
Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent technics.
Baum, J., Simons, B. E., Unger, R. H., & Madison, L. L. (1962) · PubMed · Cited by 97
Self-citationBrand, C. L., Jørgensen, P. N., Svendsen, I., & Holst, J. J. (1996) · Diabetes · doi:10.2337/diab.45.8.1076 · Cited by 94 · cited 1×
“High affinity antiglucagon antibodies have benefited diabetic animals (13), as have a variety of molecules that block binding of glucagon to the glucagon receptor and/or block its signaling (14–18).”
BackgroundInsulin and Glucagon Regulate Cytosolic Phosphoenolpyruvate Carboxykinase (GTP) mRNA in Rat Liver
BEALE, E. G., Andreone, T. L., Koch, S. R., Granner, M. A., & Granner, D. K. (1984) · Diabetes · doi:10.2337/diab.33.4.328 · Cited by 67 · cited 5×
“To assess the completeness of glucagon inactivation in the Gcgr mice, we compared the hepatic levels of P-CREB (27), a key protein in its signal transduction pathway, with those of wild-type controls.”
MethodInfluentialEffects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes.
Parker, J. C., McPherson, R. K., Andrews, K. M., Levy, C. B., Dubins, J. S., Chin, J. E., Perry, P., Hulin, B., Perry, D. A., Inagaki, T., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2079 · Cited by 65
Studies of the development of diabetic ketosis in the rat
Meier, J. M., McGarry, J. D., Faloona, G. R., Unger, R. H., & Foster, D. W. (1972) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39416-5 · Cited by 55
Self-citationIncreased amino acid clearance and urea synthesis in a patient with glucagonoma.
Almdal, T. P., Heindorff, H., Bardram, L., & Vilstrup, H. (1990) · Gut · doi:10.1136/gut.31.8.946 · Cited by 49 · cited 1×
“Amino acid deficiency has been described in glucagonoma patients (33,34), raising the possibility that Gcgr mice might have high amino acid levels, as reported by Boden et al.”
BackgroundHolste, L. C., Connolly, C. C., Moore, M. C., Neal, D. W., & Cherrington, A. D. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.3.e488 · Cited by 48 · cited 1×
“Therefore, when the liver has never experienced the action of glucagon, as in the Gcgr mice, glucose disposition without insulin is no different than when both hormones are normally active (36).”
BackgroundChrist, B., Nath, A., & Jungermann, K. A. (1990) · Biological Chemistry Hoppe-Seyler · doi:10.1515/bchm3.1990.371.1.395 · Cited by 47 · cited 2×
“Uncontrolled insulin deficiency with hyperglucagonemia is characterized by increased gluconeogenesis associated with upregulation of the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEPCK) (29,30).”
BackgroundRivera, N., Grueter, C. A., Edgerton, D. S., Rodewald, T., Neal, D. W., Nishimura, E., Larsen, M. O., Jacobsen, L. O., Kristensen, K., Brand, C. L., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.115717 · Cited by 43 · cited 1×
“These studies support the clinical utility of the development of potent Gcgr antagonists and/ or glucagon suppressors capable of eliminating the lethal glucagon-dependent component of type 1 diabetes (45).”
ResultDemonstration of Glucagon in the Stomach of Human Fetuses
Ravazzola, M., Unger, R. H., & Orci, L. (1981) · Diabetes · doi:10.2337/diab.30.10.879 · Cited by 25 · cited 1×
“It is not widely appreciated that when totally depancreatized animals or humans are deprived of insulin, there is an increased production of glucagon from extrapancreatic a-cells (37) in the stomach and upper small bowel (38–43).”
BackgroundSelf-citationGlucagon receptor antagonists for the treatment of type II diabetes: current prospects.
Djurić, S. W., Grihalde, N. D., & Lin, C. W. (2002) · PubMed · Cited by 24
Extrapancreatic glucagon in control of glucose turnover in depancreatized dogs.
Ross, G., Lickley, L. A., & Vranić, M. (1978) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1978.234.2.e213 · Cited by 16 · cited 1×
“Suppression of the extrapancreatic hyperglucagonemia restores hyperglycemia to normal (44).”
BackgroundBajorunas, D. R., Fortner, J. G., & Jaspan, J. B. (1986) · Diabetes · doi:10.2337/diab.35.8.886 · Cited by 15
Prato, S. D., Riva, F., Devidé, A., Nosadini, R., Fedele, D., & Tiengo, A. (1980) · Acta Diabetologica · doi:10.1007/bf02580992 · Cited by 13
Tanjoh, K., Tomita, R., Fukuzawa, M., & Hayashi, N. (2003) · PubMed · Cited by 7
Rivier, J., Brazeau, P., Vale, W., LING, N. C., Burgus, R. C., Gilon, C., Yardley, J. P., & Guillemin, R. (1973) · PubMed · Cited by 7
Changes in plasma glucagon after total pancreatectomy in man
Sudo, T., Suzuki, T., & Tobe, T. (1980) · Gastroenterologia Japonica · doi:10.1007/bf02773909 · Cited by 6
A-Cell and gut glucagon in normal and depancreatized dogs. Inhibition by somatostatin and insulin.
Matsuyama, T., Wider, Tanaka, R., Shima, K., Tarui, S., Nishikawa, M., & Foà, P. P. (1979) · PubMed · Cited by 4
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
Stern, J. H., Rutkowski, J. M., & Scherer, P. E. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.011 · Cited by 1,031
“Hence, inhibition of hepatic gluconeogenesis appears to provide a promising intervention to treat insulin resistance and related metabolic disorders (Lee et al., 2011; Wang et al., 2015).”
BackgroundGlucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Self-citationGuo, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0327 · Cited by 623
“On the other hand, antagonizing glucagon receptor action in type 1 diabetes induced by streptozotocin and type 2 diabetes mellitus in mice markedly reduced blood glucose levels and completely prevented diabetes (Liang et al. 2004, Sorensen et al. 2006, Ali & Drucker 2009, Lee et al. 2011).”
Background
Metadata
- Authors
- Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Albert Einstein College of Medicine (US)
- VA North Texas Health Care System (US)
- Corresponding author
- Unger, Roger H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-21
- Volume
- 60
- Issue
- 2
- Pages
- 391-397
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3028337
- OpenAlex
- W1986861420
- Cited by
- 327
- References
- 47
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 12 · 2023: 14 · 2022: 19 · 2021: 20 · 2020: 12 · 2019: 16 · 2018: 25 · 2017: 26 · 2016: 32 · 2015: 40 · 2014: 25 · 2013: 23 · 2012: 26
- FWCI
- 32.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK081194, DK081194)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon receptor, type 1 diabetes, insulin deficiency, beta cell destruction, streptozotocin, alpha cell hyperplasia, hyperglucagonemia, phosphoenolpyruvate carboxykinase, ketogenesis, hyperketonemia, glucose tolerance, free fatty acids, beta-hydroxybutyrate
- MeSH terms
- Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Enzyme-Linked Immunosorbent Assay, Fatty Acids, Glucagon, Hyperglycemia, Immunohistochemistry, Insulin, Insulin-Like Growth Factor I, Liver, Pancreas, Radioimmunoassay, Blotting, Western, Receptors, Glucagon, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.